<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Diamond不是王老五 | wechat-feeds</title><link>http://MzI5MzQ3NzA3MA.favicon.privacyhide.com/favicon.ico</link><description>定期更新免疫肿瘤数据、机制等，以及个人喜欢并翻译的外文书籍。本公众号文章均为原创，仅代表个人观点，与所供职公司无关，仅做学术交流，无任何商业目的。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 16 Mar 2021 19:20:21 +0800</pubDate><image><url>http://MzI5MzQ3NzA3MA.favicon.privacyhide.com/favicon.ico</url><title>Diamond不是王老五 | wechat-feeds</title><link>http://MzI5MzQ3NzA3MA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>写意报告丨吹尽黄沙始到金，PD-(L)1肝癌研究成败带来的启示</title><link>https://mp.weixin.qq.com/s/TEqmGDKqCfboAW5tlPzy7w</link><description></description><content:encoded><![CDATA[写意报告丨吹尽黄沙始到金，PD-(L)1肝癌研究成败带来的启示]]></content:encoded><pubDate>Tue, 16 Mar 2021 19:02:49 +0800</pubDate></item><item><title>“凭君莫话封侯事，一将功成万骨枯”</title><link>https://mp.weixin.qq.com/s/Ebbua0kQQlRTv3uGzu4Yew</link><description></description><content:encoded><![CDATA[“凭君莫话封侯事，一将功成万骨枯”]]></content:encoded><pubDate>Thu, 11 Mar 2021 15:53:06 +0800</pubDate></item><item><title>2020 WCLC| 药物研发：过去的15年如何塑造未来</title><link>https://mp.weixin.qq.com/s/dZmwty6MzDGs7Mh7OeYcFw</link><description></description><content:encoded><![CDATA[2020 WCLC| 药物研发：过去的15年如何塑造未来]]></content:encoded><pubDate>Wed, 10 Feb 2021 18:06:28 +0800</pubDate></item><item><title>2020 WCLC| US FDA基于单臂批准药物汇总</title><link>https://mp.weixin.qq.com/s/7pn-xj5TskFxHTV7LPURqg</link><description></description><content:encoded><![CDATA[2020 WCLC| US FDA基于单臂批准药物汇总]]></content:encoded><pubDate>Mon, 01 Feb 2021 19:54:39 +0800</pubDate></item><item><title>2020 WCLC| Pembrolizumab联合ipilimumab没有提升疗效</title><link>https://mp.weixin.qq.com/s/9HXdlIgXhJXx2rb__9WuWg</link><description></description><content:encoded><![CDATA[2020 WCLC| Pembrolizumab联合ipilimumab没有提升疗效]]></content:encoded><pubDate>Sat, 30 Jan 2021 20:23:36 +0800</pubDate></item><item><title>2020 WCLC| ADC崭露头角</title><link>https://mp.weixin.qq.com/s/zL6NF-LtHdW7l1jFHZlQOQ</link><description></description><content:encoded><![CDATA[2020 WCLC| ADC崭露头角]]></content:encoded><pubDate>Fri, 29 Jan 2021 19:35:28 +0800</pubDate></item><item><title>2020 WCLC| 首个RET抑制剂中国患者数据</title><link>https://mp.weixin.qq.com/s/_WO-nLHRbjf7HsYzyHuS8A</link><description></description><content:encoded><![CDATA[2020 WCLC| 首个RET抑制剂中国患者数据]]></content:encoded><pubDate>Thu, 28 Jan 2021 10:23:09 +0800</pubDate></item><item><title>U.S. FDA审批考量</title><link>https://mp.weixin.qq.com/s/lCZNm6blVwYn3mXL-pTk7A</link><description></description><content:encoded><![CDATA[U.S. FDA审批考量]]></content:encoded><pubDate>Fri, 22 Jan 2021 20:33:14 +0800</pubDate></item><item><title>2021 ASCO GI：IMbrave150更新OS和中国亚组结果</title><link>https://mp.weixin.qq.com/s/JHfm4VzJtJsvtfZ_v70rXg</link><description></description><content:encoded><![CDATA[2021 ASCO GI：IMbrave150更新OS和中国亚组结果]]></content:encoded><pubDate>Tue, 19 Jan 2021 07:50:56 +0800</pubDate></item><item><title>2021 ASCO GI (2)</title><link>https://mp.weixin.qq.com/s/s6D_S2u6BIMx0eyhP6qFGA</link><description></description><content:encoded><![CDATA[2021 ASCO GI (2)]]></content:encoded><pubDate>Sun, 17 Jan 2021 13:21:11 +0800</pubDate></item></channel></rss>